Literature DB >> 32813942

A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply.

Lisa A Jackson1, Paul C Roberts2, Barney S Graham2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32813942     DOI： 10.1056/NEJMc2026616

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  mRNA-Based Vaccines.

Authors:  Frank Kowalzik; Daniel Schreiner; Christian Jensen; Daniel Teschner; Stephan Gehring; Fred Zepp
Journal:  Vaccines (Basel)       Date:  2021-04-15

Review 2.  SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response.

Authors:  Adi V Gundlapalli; Reynolds M Salerno; John T Brooks; Francisco Averhoff; Lyle R Petersen; L Clifford McDonald; Michael F Iademarco
Journal:  Open Forum Infect Dis       Date:  2020-11-17       Impact factor: 3.835

Review 3.  Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.

Authors:  Maxwell T Finkelstein; Adam G Mermelstein; Emma Parker Miller; Paul C Seth; Erik-Stephane D Stancofski; Daniela Fera
Journal:  Viruses       Date:  2021-01-19       Impact factor: 5.048

Review 4.  mRNA vaccine for cancer immunotherapy.

Authors:  Lei Miao; Yu Zhang; Leaf Huang
Journal:  Mol Cancer       Date:  2021-02-25       Impact factor: 27.401

5.  A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.

Authors:  Yuzhong Li; Yanwei Bi; Hongjian Xiao; Yueting Yao; Xiaojuan Liu; Zhengrong Hu; Jinmei Duan; Yaoyun Yang; Zhihua Li; Yadong Li; Heng Zhang; Chen Ding; Jianbo Yang; Haiwei Li; Zhanlong He; Longding Liu; Guangnan Hu; Shuying Liu; Yanchun Che; Shixia Wang; Qihan Li; Shan Lu; Wei Cun
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

6.  Selective and noncovalent targeting of RAS mutants for inhibition and degradation.

Authors:  Kai Wen Teng; Steven T Tsai; Takamitsu Hattori; Carmine Fedele; Akiko Koide; Chao Yang; Xuben Hou; Yingkai Zhang; Benjamin G Neel; John P O'Bryan; Shohei Koide
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

7.  A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience.

Authors:  Carlos Rojas; Stephen A Spector; Bernadette Cale; Megan Loughran; Leander Lazaro; Eric Mah; Gary S Firestein; Kathryn A Gold; Mark Wallace
Journal:  J Clin Transl Sci       Date:  2022-01-12

8.  Human IgG and IgA responses to COVID-19 mRNA vaccines.

Authors:  Adam V Wisnewski; Julian Campillo Luna; Carrie A Redlich
Journal:  PLoS One       Date:  2021-06-16       Impact factor: 3.240

9.  Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, E. coli Ribonuclease I and Human RNase A.

Authors:  Shuang-Yong Xu; Alexey Fomenkov; Tien-Hao Chen; Erbay Yigit
Journal:  Front Microbiol       Date:  2021-06-11       Impact factor: 5.640

10.  Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?

Authors:  Evan J Anderson; James D Campbell; C Buddy Creech; Robert Frenck; Satoshi Kamidani; Flor M Munoz; Sharon Nachman; Paul Spearman
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 20.999
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.